Last reviewed · How we verify

NCT04776421

Diverting Ileostomy and Anal Functional Outcomes After Anus Preservation Surgery

Status unknown Last updated 8 April 2021
What this trial tests

trial testing Diverting ileostomy in Diverting Ileostomy in 300 participants. Status unknown.

Timeline
1 April 2021
Primary endpoint
1 March 2022
1 March 2023

Quick facts

Lead sponsorThe First Hospital of Jilin University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment300
Start date1 April 2021
Primary completion1 March 2022
Estimated completion1 March 2023

Drugs / interventions tested

Conditions studied

Sponsor

The First Hospital of Jilin University

Who can join

Adults 18 to 75, any sex, with Diverting Ileostomy or Middle and Low Rectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Analyze the occurrence of complications, rectal function and quality of life after anus-preserving surgery for middle and low rectal cancer, so as to evaluate the role of protective ileostomy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Diverting ileostomy

Trials testing the same drug.

Other The First Hospital of Jilin University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04776421.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing